Rufinamide-Loaded Chitosan Nanoparticles in Xyloglucan-Based Thermoresponsive In Situ Gel for Direct Nose to Brain Delivery

• 主要な著者: Avantika Dalvi (著者), Punna Rao Ravi (著者), Chandra Teja Uppuluri (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

In 2004, the US FDA approved Rufinamide, an anti-epileptic drug under the brand name Banzel®. In 2015, Banzel® received approval for its use in pediatric patients (ages 1-4 years). Rufinamide shows low oral bioavailability due to a low dissolution rate resulting in less of the drug reaching the brai...